EA201491562A1 - Антитела к big-эндотелин-1 (big-et-1) и их применения - Google Patents

Антитела к big-эндотелин-1 (big-et-1) и их применения

Info

Publication number
EA201491562A1
EA201491562A1 EA201491562A EA201491562A EA201491562A1 EA 201491562 A1 EA201491562 A1 EA 201491562A1 EA 201491562 A EA201491562 A EA 201491562A EA 201491562 A EA201491562 A EA 201491562A EA 201491562 A1 EA201491562 A1 EA 201491562A1
Authority
EA
Eurasian Patent Office
Prior art keywords
big
antibodies
disorders
endothelin
endotelin
Prior art date
Application number
EA201491562A
Other languages
English (en)
Inventor
Лори К. Мортон
Дуглас МАКДОНАЛД
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201491562A1 publication Critical patent/EA201491562A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)

Abstract

Данное изобретение относится к антителам, которые связывают big-эндотелин-1 ("big-ET-1"), и способам их применения. Согласно некоторым вариантам осуществления этого изобретения эти антитела специфически связывают big-ET-1 человека, но не связывают small-ET-1 человека (т.е. активную форму эндотелина-1, которая происходит из протеолитического расщепления big-ET-1 эндотелинпревращающим ферментом-1 [ЕСЕ-1]). Согласно некоторым вариантам осуществления этого изобретения эти антитела к big-ET-1 способны блокировать расщепление big-ET-1 посредством ЕСЕ-1. Антитела по данному изобретению применимы для лечения big-ET-1-связанных нарушений, включающих в себя нарушения гипертензии, фиброзные нарушения, нейродегеративные нарушения, ретинальные нарушения, боль и раковые заболевания.
EA201491562A 2012-02-22 2013-02-22 Антитела к big-эндотелин-1 (big-et-1) и их применения EA201491562A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261601622P 2012-02-22 2012-02-22
US201261677024P 2012-07-30 2012-07-30
PCT/US2013/027380 WO2013126740A1 (en) 2012-02-22 2013-02-22 Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA201491562A1 true EA201491562A1 (ru) 2014-12-30

Family

ID=47790543

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491562A EA201491562A1 (ru) 2012-02-22 2013-02-22 Антитела к big-эндотелин-1 (big-et-1) и их применения

Country Status (23)

Country Link
US (1) US9751932B2 (ru)
EP (1) EP2817336A1 (ru)
JP (1) JP2015509946A (ru)
KR (1) KR20140130713A (ru)
CN (1) CN104203980B (ru)
AR (1) AR090128A1 (ru)
AU (1) AU2013222203B2 (ru)
BR (1) BR112014020043A2 (ru)
CA (1) CA2864830A1 (ru)
CL (1) CL2014002232A1 (ru)
CO (1) CO7071097A2 (ru)
EA (1) EA201491562A1 (ru)
HK (1) HK1205523A1 (ru)
IL (1) IL233781A0 (ru)
MX (1) MX2014010060A (ru)
MY (1) MY169210A (ru)
NZ (1) NZ629553A (ru)
PH (1) PH12014501730B1 (ru)
SG (2) SG10201606802PA (ru)
TW (1) TWI613215B (ru)
UY (1) UY34637A (ru)
WO (1) WO2013126740A1 (ru)
ZA (1) ZA201405554B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP2016394A4 (en) 2006-04-04 2013-04-24 Singulex Inc METHOD AND COMPOSITIONS FOR HIGHLY SENSITIVE ANALYSIS OF MARKERS AND DETECTION OF MOLECULES
EP2440936A4 (en) 2009-06-08 2013-03-13 Singulex Inc GROUPS OF HIGHLY SENSITIVE BIOMARKERS
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
US9719981B2 (en) 2012-08-17 2017-08-01 Father Flanagan's Boys' Home RAC1 inhibitors for the treatment of alport glomerular disease
WO2015057906A1 (en) * 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists
CA2994544C (en) * 2015-08-03 2021-03-30 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
KR20180054701A (ko) * 2015-09-16 2018-05-24 아블렉시스, 엘엘씨 항-cd115 항체
CN108341877B (zh) * 2017-01-23 2021-04-30 吴剑波 一种抗活化凝血因子v单克隆抗体及其制备方法和用途
WO2019140324A1 (en) 2018-01-12 2019-07-18 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with etbr activation
EP3810270A1 (en) * 2018-06-19 2021-04-28 Regeneron Pharmaceuticals, Inc. Anti-factor xii/xiia antibodies and uses thereof
AU2020296105A1 (en) * 2019-06-21 2022-02-03 Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital Neutralizing antibodies to human endothelin
EP4240177A1 (en) * 2020-11-06 2023-09-13 The Regents of the University of Colorado, a body corporate Bacterial biomarker for rheumatoid arthritis and related materials and methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0331100A1 (en) 1988-03-02 1989-09-06 Takeda Chemical Industries, Ltd. Anti-endothelin antibodies and their use
CA2008122A1 (en) 1989-01-26 1990-07-26 Tetsuro Okabe Pharmaceutical composition for diseases caused by vasoconstriction
JP3017773B2 (ja) * 1989-06-22 2000-03-13 塩野義製薬株式会社 エンドセリン認識モノクローナル抗体、該抗体産生ハイブリドーマおよび該抗体を用いるエンドセリンのラジオイムノアッセイ
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
MY159787A (en) 2006-06-02 2017-01-31 Regeneron Pharma High affinity antibodies to human il-6 receptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CN101707882A (zh) 2007-04-17 2010-05-12 伊姆克罗尼责任有限公司 PDGFRβ特异性抑制剂
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
WO2011133948A2 (en) 2010-04-22 2011-10-27 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途

Also Published As

Publication number Publication date
SG10201606802PA (en) 2016-10-28
PH12014501730A1 (en) 2014-11-10
BR112014020043A2 (pt) 2017-07-04
PH12014501730B1 (en) 2014-11-10
SG11201404487SA (en) 2014-10-30
UY34637A (es) 2013-05-31
EP2817336A1 (en) 2014-12-31
MX2014010060A (es) 2014-09-22
AU2013222203B2 (en) 2017-12-07
CN104203980B (zh) 2018-01-12
AR090128A1 (es) 2014-10-22
AU2013222203A1 (en) 2014-09-18
WO2013126740A1 (en) 2013-08-29
KR20140130713A (ko) 2014-11-11
CA2864830A1 (en) 2013-08-29
NZ629553A (en) 2016-10-28
IL233781A0 (en) 2014-09-30
JP2015509946A (ja) 2015-04-02
CL2014002232A1 (es) 2015-01-16
TW201348255A (zh) 2013-12-01
US9751932B2 (en) 2017-09-05
US20130216547A1 (en) 2013-08-22
TWI613215B (zh) 2018-02-01
ZA201405554B (en) 2015-12-23
MY169210A (en) 2019-03-18
CO7071097A2 (es) 2014-09-30
CN104203980A (zh) 2014-12-10
HK1205523A1 (en) 2015-12-18

Similar Documents

Publication Publication Date Title
EA201491562A1 (ru) Антитела к big-эндотелин-1 (big-et-1) и их применения
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
EA201391668A1 (ru) Способы лечения или предупреждения связанных с холестерином расстройств
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
GT201200318A (es) Anticuerpos hacia gdf8 humano
MX2015010749A (es) Anticuerpos humanos para nav1.7.
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201370081A1 (ru) Антитела к cd48 и их применение
MY168961A (en) Antibodies to pcsk9 and uses thereof
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201792336A2 (ru) Способы лечения или предупреждения связанных с холестерином расстройств
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
PE20191347A1 (es) Anticuerpos procoagulantes
EA201101686A1 (ru) Новые композиции для лечения шмт и связанных с ней расстройств
EA201492282A1 (ru) Антагонистические антигенсвязывающие белки к двум рецепторам и их применение
EA201490539A1 (ru) Соединения и композиции в качестве ингибиторов c-kit киназы
NZ626242A (en) Anti-asic1 antibodies and uses thereof
EA201490790A1 (ru) Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1
EA202090513A1 (ru) Агенты, модулирующие функции бета-катенина, и связанные способы
EP2563794A4 (en) INHIBITORS OF TYROSINE KINASE PROTEIN ACTIVITY AND THEIR APPLICATIONS TO THE TREATMENT OF OPHTHALMIC DISORDERS
EA201890347A1 (ru) Антитела и исследования для обнаружения cd37
EA201491119A1 (ru) Мутант gdf-5 для стимулирования образования хрящей
MX2019006676A (es) Anticuerpos anti-ccl2 para el tratamiento de la esclerodermia.